Clinical trial
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or…
NCT00055757 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00055757 |
|---|---|
| Title | Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase II Trial of R115777, a Farnesyl Transferase Inhibitor, in Combination With Gemcitabine and Cisplatin in Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | tipifarnib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis |
| Enrollment | 48 |
| Start date | Oct 1, 2003 |
| Primary completion | Apr 1, 2004 |
| First posted | Mar 7, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: